Findings

What do systematic reviews say?

7 questions · 7 findings · 7 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%

SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA

Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy

It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE/FGA (very low certainty).

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
RR 2.25 [0.79, 6.43]
1 study · 54 participants
Very low

Group B antipsychotic drugs: olanzapine + supportive intervention vs placebo or supportive treatment

Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people in the prodromal stage of psychosis

It is very uncertain whether group B antipsychotic drugs: olanzapine + supportive intervention changes satisfaction with treatment: leaving the study early Endpoint data… compared with placebo + supportive intervention (very low certainty).

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
RR 1.59 [0.88, 2.88]
1 study · 60 participants
Very low

Atypical vs atypical antipsychotics (only short term)

Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

COMPARISON 1. ARIPIPRAZOLE vs OLANZAPINE

Leaving the study early · patients with schizophrenia

COMPARISON 5. ARIPIPRAZOLE may leads to higher leaving the study early compared with OLANZAPINE (low certainty).

1 finding from 1 review

Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.15 [1.05, 1.25]
9 studies · 2331 participants
Low

RISPERIDONE DEPOT vs OLANZAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.32 [1.1, 1.58]
1 study · 618 participants
Low

FLUPHENAZINE (ORAL) vs OLANZAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3 [0.33, 27.23]
1 study · 60 participants
Very low

CHLORPROMAZINE vs OLANZAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.69 [0.45, 6.4]
3 studies · 139 participants
Very low